Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. [electronic resource]
Producer: 20131210Description: 1925-8 p. digitalISSN:- 1592-8721
- Aged
- Aged, 80 and over
- Antineoplastic Agents -- therapeutic use
- Boronic Acids -- therapeutic use
- Bortezomib
- Female
- Follow-Up Studies
- Humans
- Injections, Intravenous
- Injections, Subcutaneous
- Male
- Multiple Myeloma -- drug therapy
- Neoplasm Recurrence, Local -- drug therapy
- Prognosis
- Pyrazines -- therapeutic use
- Remission Induction
- Survival Rate
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.